Biosensors, Genetic Testing & Digital Health

Critical business intelligence covering forecasts, players, case studies, opportunities and technology and market assessment

The total global spending in health care is expected to be $ 7.9 trillion in 2018. The growth in healthcare expense reflects the expansion of healthcare coverage in developing markets, the increasing care needs of elderly populations, advances in treatments and health technologies, and rising labour costs. Healthcare is moving towards democratization and personalization.

Backed up by the global trend, point-of-care biosensors, genetic testing and digital health will see significant growth and will continue expanding. Point-of-care biosensors are the devices aiming at performing the diagnostics and health monitoring close to the patient. They make health care more accessible, cheaper and faster. With the similar expectation, digital health sets up to provide better health care to a wider population by leveraging telehealth, remote patient monitoring or high-end technologies such as 5G and machine learning. On the other hand, genetic testing, and molecular diagnostics, open new opportunities and move fast to uptake the market. It provides the ultimate solution for personalized medicine and predictive health care. In the biosensor section, this forum will explain the various technologies used for biosensing, the key players utilising them, important considerations in the design and manufacturing processes. The biosensor market is currently undergoing a period of transition, with biosensors for diagnostics moving closer to the point-of-care. This forum will address the driving forces behind this global trend, outline the opportunities and discuss the likely areas of expansion in the addressable market for point-of-care biosensor market.

Genetic testing is still at its infancy with great potential. It is the most powerful tool, if not the only solution, for infectious diseases, rare and undiagnosed genetic diseases, cancer prediction and diagnostics, non-invasive prenatal testing and population sequencing. We will provide an overview of how these potential applications will revolutionise the healthcare system and open new business opportunities. Attendees will gain a thorough understanding of the emerging areas, including the areas of liquid biopsy, companion diagnostics and direct-to-consumer (DTC) business model. We will provide a holistic view of genetic testing technologies, market segments, business models and forecast.

Digital health is a transformative socio-technological model for healthcare management and delivery. This forum will cover key technology innovations and case study, the strategies to enter the connected healthcare market, and the market forecasts for diverse segments, ranging from sensors, medical wearables, networking and connectivity.

For those attending.

• The PDF files of the presentations will be available to download from this website after the sessions are ended.
• All Insight Forums will be conducted in English

Forum 4 / Agenda

21 February / Afternoon
Conference Room: 3F Room B

IDTechEx Japanese Analysts Yasuo Yamamoto will be available at this Insight Forum for further discussion.

Please join IDTechEx Analysts for lunch and networking from 13:00-14:00

Timings and the agenda are subject to change